NCT01530464View on ClinicalTrials.gov

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
High Altitude Pulmonary Hypertension
Interventions
DRUG

Aminophylline

Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.

DRUG

Ambrisentan

Drug will be administered as a single dose of 5mg, followed by a 48h washout period

DRUG

Aminophylline plus ambrisentan

Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period

Trial Locations (1)

27710

Duke Clinical Research Unit, Durham

All Listed Sponsors
lead

Thies Schroeder

OTHER

NCT01530464 - The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers | Biotech Hunter | Biotech Hunter